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Severe alpha-1-antitrypsin deficiency (AATD) is most frequently associated
with the alpha-1-antitrypsin (AAT) Z variant (E342K). ZZ homozygotes
exhibit accumulation of AAT as polymers in the endoplasmic reticulum of
hepatocytes. This protein deposition can lead to liver disease, with the
resulting low circulating levels of AAT predisposing to early-onset emphy-
sema due to dysregulation of elastinolytic activity in the lungs. An increas-
ing number of rare AAT alleles have been identified in patients with severe
AATD, typically in combination with the Z allele. Here we report a new
mutation (E75V) in a patient with severe plasma deficiency, which we des-
ignate Trento. In contrast to the Z mutant, Trento AAT was secreted effi-
ciently when expressed in cellular models but showed compromised
conformational stability. Polyacrylamide gel electrophoresis (PAGE) and
ELISA-based analyses of the secreted protein revealed the presence of oli-
gomeric species with electrophoretic and immunorecognition profiles differ-
ent from those of Z and S (E264V) AAT polymers, including reduced
recognition by conformational monoclonal antibodies 2C1 and 4B12. This
altered recognition was not due to direct effects on the epitope of the 2C1
monoclonal antibody which we localized between helices E and F. Struc-
tural analyses indicate the likely basis for polymer formation is the loss of
a highly conserved stabilizing interaction between helix C and the posthelix
I loop. These results highlight this region as important for maintaining
native state stability and, when compromised, results in the formation of
pathological polymers that are different from those produced by Z and S
AAT.
Introduction
Mutations in the SERPINA1 gene can cause activity
loss and deficiency in the circulating serine protease
inhibitor alpha-1-antitrypsin (AAT). AAT is primarily
secreted by hepatocytes and plays a key role in pro-
tecting tissues from proteolytic damage by neutrophil
elastase. Alpha-1-antitrypsin deficiency (AATD) is
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AAT, alpha-1-antitrypsin; AATD, alpha-1-antitrypsin deficiency; ER, endoplasmic reticulum; IEF, isoelectric focusing; PAGE, polyacrylamide
gel electrophoresis; RMSF, root-mean-square fluctuation.
1The FEBS Journal (2017) ª 2017 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
most commonly associated with the Z (E342K) vari-
ant, which accumulates as ordered aggregates (or
‘polymers’) in the endoplasmic reticulum (ER) of hep-
atocytes, predisposing to liver disease [1]. The conse-
quent low-circulating levels of AAT result in damage
to lung parenchyma and early-onset emphysema due
to uncontrolled activity of neutrophil elastase ([2] and
reviewed in [3]). In addition to liver tissue, polymers
are found in the circulation [4,5] and in lung bron-
choalveolar lavage fluid [6,7], where they are thought
to exert proinflammatory effects and thereby worsen
pulmonary damage in AATD [8].
In addition to the common S (E264V) and Z vari-
ants, several rare alleles have been shown to cause
deficiency, normally in association with the Z allele [9–
11]. AAT null variants are not detectable in plasma
and result from nonsense mutations, splicing muta-
tions or large deletions in the SERPINA1 gene [12]. In
contrast, missense mutations lead to synthesis of con-
formationally unstable AAT variants with a variable
tendency to form intracellular polymers and a corre-
lated degree of secretory deficiency. Rare variants
exhibiting a severe polymerogenic phenotype include
Mmalton (F52del) [13], Siiyama (S53F) [14] and King’s
(H334D) [10]. Milder polymerogenic properties have
been demonstrated for other variants, such as
Mwurzburg, Yorzinuovi, Pbrescia [9,11] and Baghdad [15].
While the frequency of individual rare variants is very
low, they collectively account for up to 20% of patho-
logical alleles in Southern European countries [12,16].
Despite the role of AAT polymer accumulation in
the molecular pathology of AATD, the structural
mechanism that underpins its formation and the
details of the molecular species present in the liver
remain a matter of debate. Of several models that have
been proposed, the classical ‘loop-sheet’ model predi-
cates the insertion of the reactive centre loop (RCL) of
one molecule into b-sheet A of another [1]. An alterna-
tive possibility, based on the crystal structure of a
recombinant trimer, involves a domain swap of three
C-terminal b-strands [17]. A third alternative, the b-
hairpin model, has been proposed, in which helix I is
unravelled and both strand 5A and the RCL mediate
intermolecular contacts [18]. However, several lines of
evidence have cast doubt on the relevance of this form
to pathological polymers in AATD, including observa-
tions made using monoclonal antibodies (mAbs). The
seminal study that proposed the b-hairpin model made
use of polymers induced by a chemical denaturant
[18], and the 2C1 mAb that recognizes polymers pre-
sent in the liver of ZZ AATD individuals does not rec-
ognize those formed under such conditions [17,19]. In
addition, the 4B12 mAb recognizes monomer and
polymer equally despite an epitope that includes helix
I, which is proposed to be displaced in the b-hairpin
model [20].
Pathological mutations in AAT and related serpins,
such as PAI-1 and antithrombin, have a distribution
that broadly correlates with patches of conserved resi-
dues [21], and collectively demonstrate the importance
of specific structural interactions for mechanism and
stability [22]. The ‘breach’ [1], ‘shutter’ [14], ‘gate’ [22]
and ‘latch’ [11] regions, all of which correspond with
pathological and subpathological mutations, are
directly associated with RCL and central b-sheet A
dynamics during protease inhibition and polymeriza-
tion.
However, residues responsible for serpin stability are
widely distributed throughout the structure [23] and
natural variants can help to pinpoint other function-
ally important regions. Here we report the identifica-
tion of Trento, a novel AAT variant found in
heterozygous association with the Z allele in a patient
with severe plasma deficiency. Trento AAT was found
to possess an E75V mutation, located in a structural
region that has not previously been associated with
AATD. It exhibited an unexpected molecular beha-
viour when characterized in cellular models of disease.
Trento produced polymers with an altered immunore-
active and electrophoretic profile, distinct from poly-
mers produced by Z and S AAT, and more consistent
with a denaturant-induced polymer form. Immunologi-
cal analysis, molecular modelling and patterns of con-
servation reveal that this is due to the loss of a crucial,
highly conserved interaction between helix C and helix
I. These data indicate that this region is important for
stability against polymerization of AAT.
Results
Identification of the AAT Trento variant
The new AAT allele was identified in a 57-year-old
male current smoker (35 pack-years) suffering from
emphysema. His spirometry values showed obstructive
defects with prebronchodilator forced expiratory vol-
ume in 1 s (FEV1) of 3.51 L (70% of predicted) and
forced vital capacity (FVC) of 4.39 L (159% of pre-
dicted). His diffusion lung carbon monoxide (DLCO)
was reduced (52% of predicted). The AAT plasma
levels were determined three times in a period span-
ning 5 months with a mean value of 22.1 mgdL1
( SD: 7.8), consistent with a severe deficiency. C-
reactive protein (CRP) was always within the normal
range (mean value 0.04 mgdL1  SD: 0.01). Genetic
analysis of the SERPINA1 gene revealed the presence
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of the Z mutation in heterozygous association with a
novel missense mutation in exon 2 (c296A>T) on an
M1Ala background, representing a nonsynonymous
glutamic acid-to-valine substitution at position 75
(E75V in conventional AAT numbering, equivalent to
p.Glu99Val using HGVS guidelines).
Neither mutation was present in a brother and a sis-
ter, while the parents could not be investigated. AAT
phenotyping by isoelectric focusing (IEF) was consis-
tent with a Z phenotype, whereas the E75V variant,
which would be expected in the pI range of the S
(E264V) variant, was barely detectable (Fig. 1). An
absence of bands characteristic of the M variant sug-
gested the presence of compound heterozygosity with
two nonwild-type alleles. After diagnosis, the patient
began receiving replacement therapy by weekly intra-
venous infusion of exogenous AAT. The E75V variant
was designated ‘Trento’, according to the birthplace of
the proband.
AAT Trento is mildly deficient in cell culture
models of AATD
Wild-type AAT is synthesized as an immature high-
mannose glycoprotein in the ER, and rapidly matures
to the complex N-glycosylated form in the Golgi with
efficient secretion into the culture medium. In contrast,
appreciable levels of the Z variant accumulate in the
ER as the high-mannose form, with a concomitantly
decreased secretion. The low level of circulating AAT
in the proband – similar to that observed in a ZZ
homozygote – suggested that the AAT Trento variant
may represent a novel Z-like severe deficiency allele.
To investigate its intracellular handling and secretion,
we expressed Trento AAT in Hepa1.6 cells and per-
formed pulse-chase experiments (Fig. 2A). The pat-
terns of intracellular maturation and secretion for
wild-type M and mutant Z AAT variants, measured
for comparison, were consistent with those reported
previously [24]. Quantification of the three variants
using densitometry (n = 2) revealed kinetics of Trento
intracellular N-glycan maturation and secretion effi-
ciency only slightly lower than those of wild-type M
AAT (Fig. 2B). The percentage of secretion after
240 min of chase, relative to the initial intracellular
AAT level, was 81.5  3.7%, 21.7  7.8% and
71.8  10.9% ( SEM) for M, Z and Trento AAT
respectively.
The mild secretory deficiency of the AAT Trento
mutant observed in the pulse-chase experiments was
confirmed by quantification of AAT in the cell culture
media following transfection of Hepa1.6 cells, by both
ELISA (n = 2) and semiquantitative dot blot analysis
(n = 4; Fig. 2C,D). This behaviour was independent of
the cellular host used for expression: similar results
were obtained when the proteins were expressed in
COS-7 (as observed below in Fig. 4) or HEK293T
(not shown) cells.
Confirmation of low Trento AAT levels in patient
plasma
The efficient secretion of AAT Trento by transfected
cells, unexpected in view of the low-circulating levels
detected in the patient, was in clear disagreement with
the generally good correlation we observe between
plasma AAT concentrations and secretion in our cellu-
lar models [9–11]. In our analysis of the pulse-chase
experiments, we observed a faster migration in SDS/
PAGE of AAT Trento compared to Z AAT. This dif-
ference was more evident following N-glycan removal
by treatment with the glycosidase PNGase F under
denaturing conditions (Fig. 3A). As the expression
plasmids were identical in every other respect, the mar-
ginal but reproducible difference in migration was
therefore a direct consequence of the amino acid sub-
stitution.
To evaluate the expression of the novel allele in the
patient, and exclude artefacts in the nephelometric
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Fig. 1. Phenotyping of the AAT Trento variant. An IEF analysis
(over the pH range 4.2–4.9) was performed on the proband’s
plasma compared with that of a known M1Z heterozygote. The
main bands corresponding with Z AAT are marked by black
arrowheads, while bands corresponding with M AAT are absent
from the sample. White arrowheads indicate two weak bands that
likely correspond to the Trento AAT mutant.
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determination of clinical samples, we took advantage
of the different migration of Z and Trento AAT
observed in SDS/PAGE (Fig. 3A). We analysed by
SDS/PAGE and immunoblot the Z/Trento AAT
plasma compared with that from a control ZZ
individual and with the supernatant of cells expressing
Trento AAT, after treating the samples with PNGase
F (Fig. 3B). The proband’s plasma showed two dis-
tinct AAT bands of similar intensity that comigrated
with the Z and Trento AAT bands in the control
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Fig. 2. Analysis of Trento AAT secretion in Hepa 1.6 cells. (A) Pulse-chase experiments on Hepa 1.6 cells expressing M, Z or Trento AAT.
Transfected Hepa 1.6 cells were pulsed with 35S-Met/Cys for 10 min and chased for the indicated times. AAT was immunoprecipitated
from cell lysates and media and analysed by 7.5% SDS/PAGE and autoradiography. Black arrowheads: immature high-mannose AAT; white
arrowheads: complex N-glycosylated AAT. (B) Densitometric analysis of the autoradiograms of pulse-chase experiments (n = 2). The relative
amounts of AAT at the different chase times with an immature ER glycosylation pattern (pink), a Golgi-associated mature glycan pattern
(grey) and present in the cell medium (light blue) are expressed as percentage (mean  SEM; n = 2) of the total amount of intracellular AAT
at the beginning of chase, which was set at 100%. (C) Cells expressing M (black), Z (red) or Trento (blue) AAT were cultured for 24 h in the
absence of serum and the AAT levels in the media were analysed by ELISA (n = 2) or (D) a semiquantitative dot blot followed by
densitometric analysis (n = 4). For each experiment, the values are expressed as a percentage of M AAT secretion and the graphs
represent the means and SEM of replicate experiments.
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Fig. 3. The effect of coexpression with the
Z variant on Trento AAT secretion. (A)
Different electrophoretic mobilities in 10%
SDS/PAGE of pulse-labelled M, Z and
Trento AAT (cell lysates, chase time 0), with
or without digestion with PNGase F. (B) Z/
Trento plasma was compared by 10% SDS/
PAGE and anti-AAT immunoblot with that of
a control ZZ patient and with Trento AAT in
cell media, after treatment with PNGase F.
(C) Hepa 1.6 cells were transfected with
plasmids encoding Trento (blue) and Z (red)
AAT alone or mixed at 1 : 1 and 1 : 2
(Trento : Z) ratios (purple/pink), keeping the
total amount of transfected DNA constant.
Levels of AAT in the cell media were
determined by ELISA (n = 2) and expressed
as percentage of secreted AAT normalized
to Trento (mean  SEM). Observed (Obs)
values are compared to the values
predicted (Pred) from secreted amounts of
the variants expressed alone. One-way
ANOVA P < 0.0001. (D) Upper panel:
Proteins in the cell media quantified in panel
C were deglycosylated with PNGase F and
analysed by 11% SDS/PAGE and
immunoblot to separate Z and Trento AAT.
Lower panel: The ratio of Z (red) and Trento
(blue) were determined by densitometry of
immunoblots in n = 2 experiments and
represented in the graph as fractions of
secreted AAT (mean  SEM). (E) Hepa 1.6
cells were cotransfected with plasmids
encoding for the tagged variants Trentomyc
and ZHA and analysed by confocal
microscopy. Cells were labelled with a
rabbit anti-myc polyclonal antibody and a
mouse anti-HA mAb; followed by 488 nm
ALEXA-conjugated anti-rabbit and 594 nm
ALEXA-conjugated anti-mouse secondary
antibodies. Micrographs were acquired by
the LSM510META confocal microscope
(Zeiss) with a EC Plan-Neofluar 100x/1.30 oil
objective. (F) Colocalization was analysed by
the Colocalization Threshold Tool in ImageJ
[50] and represented in white colour. The
scatter plot shows an overall colocalization
of the two variants. The Trento variant is
also localized in a perinuclear region likely
corresponding to the Golgi apparatus, as
highlighted in the magnification box and the
relative scatter plot.
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lanes, confirming a Z-like circulating level for Trento
AAT.
Z AAT does not exert a dominant retention effect
on Trento AAT
It has been observed that the Z AAT variant can
copolymerize with other mild deficiency variants of
AAT [25]. To investigate whether the low level of
Trento AAT observed in the proband’s plasma was
due to a dominant retention effect exerted by Z AAT,
we performed coexpression experiments. Hepa 1.6 cells
were transfected with plasmids encoding Trento or Z
AAT alone, or with plasmid mixes at either 1 : 1 or
1 : 2 ratios, keeping the total amount of transfected
DNA constant. Determination of the resulting AAT
levels in the cell media by ELISA (n = 2) showed that
coexpression did not reduce total secreted AAT rela-
tive to our prediction based on the levels of the two
variants alone. The average value of Trento AAT was
set at 100% and the observed percentages were
100  9.4% and 34.5  3.8% ( SEM) for Trento
AAT and Z AAT alone, and 63.7  9.4 and
50.9  7.4 for the 1 : 1 and 1 : 2 coexpression condi-
tions respectively (Fig. 3C).
The cell media supernatants were then analysed by
SDS/PAGE and immunoblot after deglycosylation
with PNGase F in order to distinguish between
secreted Z AAT and Trento AAT (Fig. 3D, upper
panel). The proportion of Trento AAT and Z AAT in
the secreted material analysed in Fig. 3C was quanti-
fied by densitometric analysis of the bands of both
variants in two distinct experiments (Fig. 3D, lower
panel). The absence of substantially reduced secretion
of Trento during coexpression with Z AAT makes this
unlikely to be the cause of the low Trento AAT levels
observed in the patient’s plasma. Again, this was not
cell-line specific: similar results were observed during
coexpression of Trento and Z AAT in HEK293T cells
(data not shown).
Taken as a whole, the secretion data are consistent
with a protein that folds and is secreted at near wild-
type levels, in contrast to the Z variant which is
known to exhibit delayed folding [26] and compro-
mised secretion. The intracellular localization of
Trento and Z AAT, respectively, modified with -myc
and -HA tags, was also studied by confocal
immunofluorescence microscopy (Fig. 3E), and showed
an enrichment of Trento AAT in a region most proba-
bly corresponding to the Golgi apparatus when com-
pared to Z AAT (Fig. 3F), consistent with its more
efficient secretion.
Trento AAT forms polymers with reduced
reactivity to conformation-selective antibodies
To investigate whether the new AAT variant forms
polymeric structures, we expressed the protein in
COS-7 cells, using M, Z and the highly polymerogenic
King’s AAT (H334D) [10] for comparison. The intra-
cellular lysates and culture media of transfected cells
were analysed by SDS- and nondenaturing PAGE fol-
lowed by immunoblot with a rabbit anti-AAT poly-
clonal antibody that recognized all conformations of
AAT (Fig. 4A). As observed for Hepa1.6 cells, Trento
AAT was secreted at higher levels than the severe defi-
ciency Z and King’s (H334D) AAT (Fig. 4A, upper
panel). Under nondenaturing conditions, both mono-
meric and higher molecular weight forms were evident
for Trento AAT, in common with the Z and H334D
variants (Fig. 4A, lower panel). The immunoblot
membrane was subsequently reprobed with mAb 2C1,
which recognizes polymers isolated from ZZ tissue
and heat-induced polymers to a greater extent than
denaturant-induced polymers [10]. This antibody was
able to specifically recognize a polymeric ladder in cell
lysates and culture supernatants, albeit to a noticeably
lesser degree for Trento AAT relative to the other
mutants (Fig. 4B). This effect was particularly promi-
nent for polymers present in the cell media super-
natant. AAT Trento polymers were also detected less
efficiently by the 4B12 mAb (Fig. 4C), whose epitope
spans the A and I helices and recognizes Z AAT poly-
mers [20].
To evaluate the differential recognition of the AAT
variants using a more quantitative technique, the
affinities of mAbs 2C1 and 4B12 for M, Z and
Trento AAT relative to 9C5 (a reference mAb with
good affinity for all conformers of AAT [10]) were
also evaluated by sandwich ELISA (Fig. 4D). These
experiments confirmed an approximately 10-fold
decrease in recognition of Trento AAT polymers by
both mAb 2C1 and 4B12 with respect to M and Z
AAT.
Localization of the 2C1 epitope to the region
between helices E and F
As the epitope of mAb 2C1 has not yet been deter-
mined, it is possible that the E75V mutation could
directly alter this epitope and reduce the affinity for
Trento AAT polymers. To ascertain this, a protec-
tion assay using the thiol-reactive fluorophore 7-
diethylamino-3-(4-maleimidophenyl)-4-methylcoumarin
(CPM) was developed to map the binding site of
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mAb 2C1. This approach was validated using mAb
4B12, whose epitope has been localized using
PEGylation and spin-labelling [20]. Monomeric sin-
gle-cysteine recombinant mutants were incubated
with the 4B12 antibody, the CPM fluorophore was
added, and the increase in fluorescence due to thiol
conjugation was followed over time. Increased pro-
tection of a cysteine against conjugation due to the
binding of the antibody resulted in a reduced label-
ling efficiency and a concomitant decreased overall
fluorescence. The resulting curves exhibited good cor-
respondence with the previously determined 4B12
epitope, including a lack of interaction at position
74 on helix C (Fig. 5A, left, shaded bars). This sug-
gests that reduced binding of the 4B12 antibody to
Trento AAT is not due to direct effects by the
E75V mutation on the epitope, but rather through
indirect structural changes.
For experiments with mAb 2C1, the single-cysteine
mutants were subjected to heat-induced polymerization
prior to incubation with the antibody. However, muta-
tions near E75, including 29, 74 and 81, showed no
effect, while 2 of 11 mutants surveyed – 139 and 155 –
exhibited a reduced degree of fluorophore conjugation
in the presence of 2C1 (Fig. 5A, right, white bars).
This is consistent with an earlier observation [10] in
which a stabilizing G117F mutant was noted to form
polymers that were not recognized by 2C1: positions
139 and 155, on helix E and F respectively, flank this
site (Fig. 5B, left panels). The G117F mutation leads
to a network of structural changes; comparison of sur-
face patches of G117F to the wild-type recombinant
protein reveals the greatest surface difference between
these two variants occurs on the face bounded by
helices E and F (Fig. 5B, right panels). Further sup-
port for this epitope localization comes from a study
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Fig. 4. Polymers of Trento AAT are
differentially recognized by conformation-
specific mAb. (A) COS-7 cells were
transiently transfected with the AAT
variants as indicated, and the soluble cell
lysate and culture media collected after
48 h were resolved by SDS or
nondenaturing PAGE, followed by western
blot with a rabbit polyclonal anti-AAT (Rb
AAT). (B) The same membrane in (A) for the
nondenaturing PAGE was immunostained
with mAb 2C1 (anti-AAT polymer). (C)
Equivalent samples to (A) and (B) were
resolved in a parallel membrane and probed
with mAb 4B12. (D) Affinity curves of three
mAb [9C5 (black), 2C1 (red) and 4B12
(blue)] by sandwich ELISA, using culture
medium supernatants of COS-7 cells
transfected as in (A) with M, Z or Trento
AAT as the antigens. The graphs shown are
representative of three independent
experiments with similar results.
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Fig. 5. Localization of the mAb 2C1
epitope. (A) Single-cysteine mutants
(0.1 mgmL 1 final concentration) in the
presence and absence of a 0.5 : 1 molar
ratio of mAbs 4B12 (cyan/green) or 2C1
(white/blue) were incubated with the CPM
dye. The change in fluorescence (excitation
370 nm and emission 490 nm) was
monitored for 30 min. The fractional
intensity of each curve in the presence of
the antibody was calculated with respect to
its absence. This property reflects the
degree of the exposure of the single
cysteine; a lower value in the presence of
an antibody is indicative of shielding due to
binding. Green bars indicate positions
previously identified in the 4B12 epitope;
blue bars indicate sites of shielding in the
presence of the 2C1 antibody. Values
represent mean  SEM (n = 4, except: a
denotes n = 2; b, n = 3; c, n = 5). (B) Left
panels: Two residues identified by this
approach are shown as blue spheres on a
cartoon representation of cleaved AAT (PDB
accession 1EZX) in addition to the location
of the G117F mutation that yields polymers
nonreactive with 2C1 [10] in magenta and
the Trento mutation at 75 is shown in black.
Helices C, E and F are in cyan, and b-sheets
A, B and C are in red, pink and yellow
respectively. Right panels: a comparison of
surface patches between wild-type M AAT,
which produces 2C1-recognized polymers,
and the G117F mutant, which does not. For
each surface-accessible residue on wild-
type recombinant AAT (PDB accession
1QLP), an epitope-sized surface patch was
defined comprised of all positions with a Ca
atom within 8 A of this central site. Each
patch was then optimally aligned against
identical residues in the crystal structure of
G117F (accession 3DRU), the root-mean-
square deviation between equivalent
backbone Ca atoms was calculated, and the
value was mapped onto the original central
surface-accessible residue. This method of
structural comparison has been described
elsewhere [38]. Blue denotes the centre of
patches with a high degree of similarity
between the structures, and red denotes a
high degree of structural divergence. Grey
indicates patches that overlap glycan
attachment sites; as 2C1 binds to
glycosylated material, the epitope would not
overlap with these positions. The figure
was generated using PyMol (Schrodinger).
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in which a disulphide bond engineered to restrict
movement of helix F resulted in polymers that were
also only marginally detectable by 2C1 [27]. These col-
lective data are consistent with an epitope that lies
within the helix E/F interhelical region. This region is
notable for undergoing change during the five- to six-
stranded transition of b-sheet A, and is the site of
binding of antagonists of conformational change –
vitronectin by PAI-1 [28] and an N-terminal extension
by tengpin [29]. In regard to Trento AAT, the position
of the mAb 2C1 epitope on the opposite side to helix
C (Fig. 5B, lower panels) indicates that the decreased
reactivity with the antibody is not due to direct effects
of the E75V mutation on binding. This makes it likely
that 2C1 is reporting a change in the nature of the
polymer itself.
The oligomeric pattern of Trento AAT resembles
polymers prepared in vitro under denaturing
conditions
The pathway of polymer formation has multiple steps
and several alternative outcomes. Under certain condi-
tions, different intermediates [30–32], polymer states
[17,19,33] and the latent conformation [34,35] are
potentially accessible during polymerization. One rep-
resentation of the pathway represents the transition
between monomer (M), monomeric intermediate (M*),
polymer (P) and the monomeric, inactive latent form
(L):
M ↔ M* (+M*) → P
↓
L
A difference in the affinity of conformation-specific
mAbs for polymers of AAT Trento is a reflection of
structural changes in their respective epitopes. These
changes may be associated with altered rates and pre-
ferred species along the polymerization pathway, such
as at the monomer activation and monomer addition
steps. The electrophoretic profile following separation
by nondenaturing PAGE can provide a sensitive mea-
sure of this; heat-induced polymers exhibit a distribu-
tion enriched for high molecular weight oligomers,
whereas treatment with denaturants results in a pre-
ponderance of lower molecular weight species
[19,32,36,37]. Z and Trento AAT were purified from cell
culture media of transfected HEK293T cells by affinity
chromatography and analysed by nondenaturing
PAGE, with visualization by silver staining (Fig. 6A) or
immunoblotting (Fig. 6B). Although Z AAT showed an
accumulation of higher molecular weight bands that
were well recognized by mAb 2C1 (also seen in Fig. 4),
AAT Trento favoured a dimeric form that was less reac-
tive to mAb 2C1 than higher order oligomers.
The electrophoretic profile obtained for Trento AAT
exhibited the hallmarks of AAT treated with denatur-
ing agents. To confirm this, we compared the migra-
tion by nondenaturing PAGE of AAT Trento purified
from cell media to that of Z and S AAT purified from
plasma samples and polymerized either by heating for
4 h at 55 °C or by exposing for 30 h at room tempera-
ture to 3 M urea or 3 M guanidinium hydrochloride
(Fig. 6C). Although the profile of Z AAT resembled
higher molecular weight heat-induced polymers for
which 2C1 shows high affinity, that of Trento AAT
was more similar to the pattern of low molecular
weight polymers of Z and S AAT prepared in the pres-
ence of denaturants.
Trento AAT is conformationally unstable at
physiological temperatures
To investigate the stability of the mutant proteins
under physiological conditions, we collected cell media
supernatant from COS-7 cells transfected with M, Z
and Trento AAT for 48 h, and incubated it in the
absence of cells at 37 °C for 0, 24, 48 or 72 h. The
samples were analysed by nondenaturing PAGE fol-
lowed by immunoblot (Fig. 6D). In contrast to M and
Z AAT, monomeric Trento AAT was found to con-
vert into slower and faster migrating bands in the
vicinity of the original monomeric species (Fig. 6D,
white arrowheads), indicative of alternative conforma-
tions [19,34,35]. The latter band is likely to be the
latent species, a monomeric conformation in which the
protein has become inactivated through incorporation
of the RCL into b-sheet A without cleavage [34].
Under these conditions, we did not observe an
increase in polymeric forms, possibly due to the low
concentration of the mutant protein in the culture
medium supernatants and stabilizing factors that are
known to be present in the medium [38]. We therefore
repeated the experiment by incubating affinity-purified
Trento AAT at 37 °C for 24 and 48 h in PBS
(Fig. 6E). We observed a reduction in the intensity of
the monomer band and an increase in the oligomer
species. The presence of polymeric species was con-
firmed by native PAGE analysis of the proband’s
plasma (Fig. 6F). The latent and polymeric forms
reflect two outcomes that can arise from the common
process of activation to polymer-prone intermediate
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[39]. Both these experiments therefore show the native
state instability of Trento AAT at physiological tem-
perature.
The side chain of E75 is a molecular spacer
critical for maintaining native contacts
These collective results indicate that Trento AAT folds
efficiently in the ER to a conformation that stays
partly monomeric and partly becomes oligomeric, is
compatible with secretion, and that the monomeric
form is unstable. Position 75 is located on helix C, and
in the native state, the glutamic acid side chain forms
hydrogen bonds with the backbone atoms of T309 and
K310, situated C-terminal to helix I. In combination
with a hydrogen bond formed by T72, these interac-
tions stabilize the posthelix I loop (Fig. 7A). A com-
parison with the crystal structures of other native
serpins reveals that this is a strongly geometrically
conserved interaction that yields a precise distance
between the two helices (Fig. 7B, right). This is high-
lighted by an analysis of the evolutionary substitution
pattern at this position: where a replacement has
occurred, this is almost exclusively with a glutamine
residue (Fig. 7B, left), which has an identical side-
chain length. The striking absence of chemically simi-
lar residues that are one carbon shorter – aspartic acid
and asparagine – supports a role for this position as a
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molecular ‘spacer’ between helix C and the posthelix I
loop, with a critical length and orientation.
This high degree of conservation is strongly support-
ive of a role for E75 in maintaining a functional inhi-
bitor. Our cell secretion results indicate that, while
AAT can adopt an ordered, folded conformation in
the absence of this spacer residue, it readily becomes
inactivated through polymerization. To explore the
structural consequences in the vicinity of the mutation,
a molecular dynamics (MD) analysis was performed.
For each MD simulation, the root-mean-square fluctu-
ation (RMSF) of Ca atoms of all residues was calcu-
lated for the wild-type and for the Trento AAT
mutant, in order to analyse how the mobility of differ-
ent portions of the structure is affected by the muta-
tion. As shown in Fig. 7C, there are two main regions
where the mutant has a significantly higher mobility
with respect to the wild-type: the first is on helix C
close to the mutation site, involving residues from 70
to 80; the second is on helix I, involving residues from
300 to 320. Additionally, lower RMSF values of the
mutant were observed in the region involving residues
from 130 to 140. Analysis of hydrogen bonds and salt
bridges suggests that the pattern of contacts is altered
in the mutant protein (Table 1).
Discussion
Managed instability is crucial for the physiological
inhibitory mechanism of AAT. During the interaction
with elastase, a concerted change occurs in which
unfavourable interactions distributed throughout the
molecule are resolved, with a rapid transition to an
energetically favoured inactive conformation. With
involvement of a large proportion of the molecule in
the metastable-to-stable transition, mutations that pro-
mote aberrant inactive conformations show a wide dis-
tribution throughout the structure. These mutations,
when associated with misfolding and polymerization,
can cause circulating deficiency, proteolytic dysregula-
tion, and gain-of-function toxicity in affected individu-
als. Correspondingly, given the complex interplay
between serpin stability and function, pathological
variants have proven invaluable for identifying regions
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Fig. 7. Structural characterization of the E75V mutation. (A) Structural detail of the vicinity of the E75 residue, with helix B in blue, helix C in
green, helix I in pink and the posthelix I loop in transparent red, showing the polar interactions mediated by E75 and T72. (B) A comparison
of antitrypsin (1QLP, green), neuroserpin (3FGQ, magenta), plasminogen activator inhibitor-1 (3Q02, yellow) and a Thermobifida fusca
bacterial serpin (1SNG, blue), showing the evolutionarily and geometrically conserved interaction between Glu75 and the backbone of
residues 309–310 (AAT numbering). Patterns of conservation within helix C are represented to the left using Weblogo [51], calculated from
the PFAM ‘seed’ alignment of the serpin superfamily (PF00079), after indels were manually adjusted to account for secondary structure. (C)
RMSF of backbone atoms averaged over 10 independent 10-ns all-atom simulations at 310K of M (blue) and Trento AAT (red), with
cylinders highlighting the structural elements (in the vicinity of helices C, D, E and I) whose mobility is affected by the presence of the
mutation. The figure was generated using PyMol (Schrodinger).
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and interactions of mechanistic and structural impor-
tance.
Intracellular polymer formation, whether the cause
or a consequence of mutant AAT retention within the
ER, is a key pathogenetic mechanism in AATD associ-
ated with polymerogenic AAT variants. However, the
polymer structure(s) and the polymerization mecha-
nisms in vivo have not been elucidated and are still the
subject of debate. This is confounded by the observa-
tion that different in vitro conditions can favour the
production of qualitatively different polymers [17,40].
The polymerization pathway therefore passes through
‘decision-points’ which favour or disfavour particular
alternate structural outcomes, although whether some
alternate forms ever arise in vivo remains uncertain.
For example, it has been shown that the experimen-
tally inducible monomeric, inactive latent conforma-
tion of AAT is effectively absent from individuals with
the pathological Z variant [35]. Additionally, the 2C1
antibody that recognizes pathological Z polymers and
heat-induced polymers can immunodeplete all material
in a cellular expression system, suggesting an absence
of the denaturant-induced form for Z AAT in vivo
[10].
The variant we describe here, identified in an indi-
vidual exhibiting severe AATD, is the first description
of a pathological mutation of AAT situated on helix
C. An examination of other serpins highlights the
coordination by the E75 side chain of a highly con-
served geometry between helices C and I through sta-
bilization of the posthelix I loop. Loss of this
interaction results in the formation of polymers with a
profile distinct from that of Z and heated M AAT.
The presence of distinct electrophoretic ‘fingerprints’
for heat-induced and denaturant-induced polymers can
be observed in publications by several groups
[19,32,36,37]; however, this is the first description of
such behaviour in a natural AAT variant. The polymer
size distribution in nondenaturing PAGE, coupled
with the relative affinity of the 4B12 and 2C1 antibod-
ies, suggests that polymers formed by Trento AAT
likely correspond to denaturant polymers. In contrast,
those of the Z variant produced in the same cellular
system exhibited heat-like characteristics; this prior
observation [19] has questioned the relevance of exper-
iments performed in the presence of denaturant to
pathological and heat-induced polymers. However, the
data presented here indicate that these studies may
provide insight into the behaviour of Trento AAT:
polymerization of Trento AAT would be expected to
proceed via an expanded (rather than compact) molten
globule-like intermediate [31], involve destabilization
of helix I [18] and possibly strand 5A [17], and favour
dimer addition over monomer addition [32].
The currently proposed models of polymerization all
agree that the RCL and b-sheet A are central to the
polymerization mechanism, although they disagree in
which capacity. Accordingly, ‘breach’ (such as Z) and
‘shutter domain’ (such as Siiyama and Mmalton) variants
have been identified which impact directly on these
structural elements [13,14,22]. The observation that the
epitope of 2C1, with its high degree of specificity for
polymer, is situated in a region that is indirectly but
substantially involved in RCL insertion is consistent
with this. In contrast, the location of E75V on helix C
is outside of these core functional regions, and its
effect is highly likely to be mediated by the loss of the
interaction with helix I. The involvement of helix I in
conformational change was shown by a study in which
subtle helix I mutations were found to alter inhibitory
activity [41]. Correspondingly, MD simulations show a
destabilization of both helices C and I for the Trento
AAT mutant. The importance of this region for the
process of polymerization is highlighted by a mAb that
suppresses polymerization in PAI-1 with an epitope
that includes position 74 on helix C [42], and the 4B12
mAb that reduces AAT polymerization with an epi-
tope that includes position 306 of helix I [20]. This is
further underscored by the striking conservation of
either a glutamic acid or glutamine residue at this site
throughout the serpin protein family.
In the proband, which shows very low AAT plasma
levels and severe pulmonary manifestations, Trento
AAT is expressed in compound heterozygosity with Z
AAT. Our observation that the new mutant was only
mildly deficient in cellular models prompted us to inves-
tigate whether this phenotype was due to a dominant
effect of the Z variant. SERPINA1 alleles are expressed
codominantly, and plasma levels of AAT in
Table 1. Summary of key hydrogen bonds during MD simulations.
The average number of hydrogen bonds between selected pairs of
residues was calculated over the course of the MD simulations of
wild-type M and of Trento AAT variants. The difference between
these values as a result of the Trento mutation is shown in the last
column.
Donor Acceptor M Trento Difference
Glu/Val 75 Thr 309 1.28 0.00 1.28
Glu/Val 75 Lys 310 1.13 0.00 1.13
Thr 72 Asp 317 0.91 0.57 0.34
Val 311 Leu 329 0.95 0.71 0.24
Asn 116 Ser 140 0.65 0.86 0.21
His 73 Glu 89 0.07 0.25 0.19
Ala 70 Asp 317 0.00 0.12 0.12
Lys 135 Glu 141 0.25 0.36 0.11
Asp 71 Asp 317 0.00 0.11 0.11
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heterozygous patients are thought to result from the
independent contributions of the two variants. How-
ever, hetero-polymerization of the S and Z variants of
AAT has been demonstrated by in vitro studies [25],
and an example of heterotypic interactions has been
reported in cells between Z and I (R39C) AAT [24]. On
this basis, we investigated whether Z AAT coexpression
could exacerbate retention of Trento AAT, but this was
found not to be the case. Our cellular experiments indi-
cate that instead Trento AAT is secreted at almost
wild-type levels, without the delay seen with Z AAT.
This suggests that it is able to fold efficiently to confor-
mations that negotiate export from the ER and transit
through the secretory pathway, and the conformational
instability is manifested most prominently once in the
native state. Our previous studies have shown that
polymers of Z AAT form within the ER and are
secreted from cultured cells, consistent with an intracel-
lular origin for Z AAT polymers found in human
plasma [5]. Still, the differences in Trento AAT polymer
characteristics shown here leave the question open as to
whether extracellular Trento AAT polymers behave in
a similar fashion, or whether they form directly after
monomer secretion into plasma.
Our results do not explain the marked absence of cir-
culating Trento AAT observed in the patient. It can be
speculated that the low levels present are due to the
instability of the mutant under physiological conditions:
our results suggest that the Trento mutation could facil-
itate the transition of AAT to latent and/or polymers
in plasma, as seen for other serpins like antithrombin
[43]. There is evidence that the circulating half-life of
polymers is considerably lower than that of the mono-
meric protein, at < 30 h [4] and 4–6 days [44] respec-
tively. Additionally, latent Trento AAT could be prone
to interactions with circulating proteins and/or cells in
plasma, which might enhance its clearance. The clear-
ance mechanisms for latent and polymeric AAT have
not yet been elucidated, but our results suggest further
investigation is warranted, in order to assess turnover
of aberrant AAT conformers in the circulation.
Experimental procedures
Genetic identification of the E75V mutation and
phenotyping
Biochemical and genetic tests to diagnose AATD were per-
formed at the Centre for Diagnosis of Inherited Alpha1-
Antitrypsin Deficiency at Fondazione IRCCS Policlinico
San Matteo (Pavia, Italy) with the understanding and writ-
ten consent of each subject. All methodologies were in
accordance with the Declaration of Helsinki and were
approved by the local ethics committee. The plasma levels
of AAT and CRP were determined by a rate immune neph-
elometric method assay (Immage Immunochemistry Sys-
tem; Beckman-Coulter, Milan, Italy). DNA was isolated
from whole peripheral blood using a commercial extraction
kit (DNA IQ System; Promega, Milan, Italy). Genotyping
for detection of the S and Z variants was performed by
PCR/RFLP, as previously described [45]. The new muta-
tion was identified by sequencing all coding exons (II-V) of
the SERPINA1 gene (RefSeq: NG_008290) as reported pre-
viously [46], using the CEQ 8800 genetic analysis System
(Beckman Coulter). The phenotype of the new variant was
determined by IEF analysis on plasma samples, comparing
it with other plasma of known phenotype in a pH gradient
of 4.2–4.9 (Multiphor II Electroforesis System; GE Health-
care BioScience, Milan, Italy), as previously described [46].
The clinical data were obtained from direct observation of
clinical charts and they are reported in an anonymized form.
Expression vectors, cell lines and transfections
The pcDNA3.1/Zeo (+) expression vectors encoding for
human M1(Val213) and Z AAT have been previously
described [47]. The Trento mutation (c296A>T) was intro-
duced into the vector encoding M1 AAT by Site-Directed
Mutagenesis Kit, Stratagene, Agilent, Roma, Italy), according
to the manufacturer’s instructions, using a 50-ctgacactcacgatg-
taatcctggagggcct primer and its reverse complement. COS-7
cell transfection used previously reported pcDNA3.1 plasmids
encoding M, Z and H334D AAT [10]. The AAT variants were
expressed by transient transfection in Hepa 1.6, COS-7 or
HEK293T cell lines (ATCC #1830, #1651 and #11268 respec-
tively) maintained in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% FBS (Sigma-Aldrich, Milan, Italy).
Transfections in COS-7 cells in six-well plates were performed
by Lipofectamine2000 (Life Technologies, Monza, Italy)
according to the manufacturer’s protocol, using 4 lg DNA
and 10 lL Lipofectamine in serum-free Optimem (Life Tech-
nologies) for 6 h. Hepa1.6 cells and HEK293T cells were
transfected by Polyethylenimine ‘Max’ (PEI, PolySciences
Inc, Hirschberg, Germany). DNA–-poly(ethylenimine) com-
plexes were made in serum-free DMEM (3 lg DNA and
18 lg poly(ethylenimine) in 400 lL for 10 cm2 plates) and
then added to cells in normal culture medium for 5 h.
Immunofluorescence and confocal microscopy
For immunofluorescence staining, Hepa 1.6 cells grown on
coverslips were cotransfected with plasmids encoding
Trentomyc and ZHA. After 24 h, the cells were fixed with 4%
paraformaldehyde and permeabilized with 0.1% Triton
X-100. Staining was performed with a rabbit anti-myc poly-
clonal antibody (Sigma-Aldrich) and a mouse anti-HA mAb
(Sigma-Aldrich); followed by 488 nm ALEXA-conjugated
anti-rabbit and 594 nm ALEXA-conjugated anti-mouse
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secondary antibodies (Thermo Fisher Scientific, Monza, Italy).
Coverslips were mounted with 50% glycerol in PBS and
analysed by the LSM510META confocal microscope (Zeiss,
Milan, Italy) with a EC Plan-Neofluar 1009/1.30 oil objective,
using the 488 nm or 543 nm lasers in multitrack mode.
Pulse-chase experiments
Pulse-chase experiments were performed as previously described
[24]. Twenty-four hours after transfection, Hepa 1.6 cells were
pulsed for 10 min with 35S Met/Cys (EasyTagTM Express Protein
Labelling mix; Perkin Elmer, Milan, Italy) and chased for 0, 15,
30, 60, 120 or 240 min. At each time point, cell culture media
were collected and the cells were lysed in a buffer containing
50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 1% NP40, 10 mM N-
ethylmaleimide and protease inhibitors (Sigma-Aldrich). The
cell lysates were centrifuged at 3000 g. AAT in the cell lysates
and culture media were immunoprecipitated using anti-AAT
polyclonal antibodies (DAKO, Milan, Italy) and PGAgarose
(Thermo Fisher Scientific), and then analysed by 7.5% SDS/
PAGE followed by autoradiography.
SDS/PAGE, nondenaturing PAGE and western
blot analysis
SDS/PAGE and nondenaturing PAGE of cell lysates and
media were performed as previously described [11,48]. Mem-
branes were probed with either a commercial anti-AAT poly-
clonal (DAKO), the 2C1 mAb [10] or the 4B12 mAb [38],
and then revealed with HRP-conjugated secondary antibod-
ies (Sigma-Aldrich) and ECL (EuroClone S.P.A., Milan,
Italy).
PNGase F treatment
Digestion with PNGase F (New England BioLabs, through
Euroclone S.P.A.) was performed according to the manu-
facturer’s protocol on undiluted cell media or on plasma
samples diluted 1 : 200 with PBS. The samples were dena-
tured at 94 °C for 10 min in denaturing buffer/DTT, then
diluted in 50 mM phosphate buffer pH 7.5 containing 1%
NP40 and incubated for 1 h at 37 °C.
Expression and purification of AAT variants from
cell media or plasma
For purification of Trento and Z AAT from cell media,
HEK293T cells were transfected with poly(ethylenimine)
and incubated in serum-free DMEM for 36 h. The condi-
tioned medium was collected, centrifuged for 5 min at
3000 g, and AAT was purified by affinity chromatography
on Alpha-1 Antitrypsin Select (GE Healthcare). About
36 mL of cell supernatant was loaded onto 500 lL of
matrix, washed with 150 mM NaCl/20 mM Tris pH 7.4 and
eluted with 1 mL of 2 M MgCl2/20 mM Tris pH 7.4. The
purified samples were desalted by Amicon Ultra-0.5 cen-
trifugal Filter devices (Millipore, Merck, Milan, Italy). A
similar protocol was used to purify S and Z from plasma
diluted 1 : 5 with 150 mM NaCl/20 mM Tris pH 7.4. Poly-
merization of purified proteins at 1–5 lM concentration in
phosphate buffer pH 7.4 was induced either by heating at
55 °C for 4 h or by treating for 30 h at room temperature
with 3 M GuHCl or 3 M urea.
Sandwich ELISA
Ninety-six-well plates (Corning) were coated with antigen-
purified rabbit polyclonal anti-AAT antibody (2 lgmL 1),
washed (0.9% w/v NaCl, 0.05% v/v Tween20) and blocked
with blocking buffer (PBS, 0.25% w/v bovine serum albu-
min, 0.05% v/v Tween20). Standards (purified M AAT or
polymerized Z AAT) and samples were diluted in blocking
buffer and incubated for 2 h at 37 °C. After washing, wells
were incubated with either sheep anti-AAT-HRP (Abcam,
Cambridge, UK) for AAT quantification, or with mAbs
2C1, 4B12 or 9C5 followed by anti-mouse IgG horseradish
peroxidase-labelled antibody for affinity comparison, as
indicated in the figure legends. HRP activity was measured
by reaction with TMB and absorbance at 450 nm read on
standard plate readers (Promega Glomax plate reader or
Perkin Elmer Ensight).
Recombinant expression and epitope mapping
Single-cysteine variants of AAT with the C232S mutation
were generated and expressed in Escherichia coli as
described previously [20]. Polymerization was induced at a
concentration of 0.25 mgmL 1 in PBS with 0.5 mM
Tween-20 by heating at 55 °C for 1 h. Monomeric or poly-
meric protein was incubated at a concentration of
0.2 mgmL 1 and 35 lL volume with 0.5 : 1 molar ratio
of monoclonal antibody (or in its absence) for 20 min at
room temperature. CPM dissolved at a concentration of
100 mM in DMSO was rapidly diluted 1 : 5000 into PBS,
and an equal volume was added to each sample. The conju-
gation reaction was monitored for 30 min using a Spec-
traMax M5 plate reader (Molecular Devices; em = 490 nm,
ex = 370 nm). A Python/NumPy script was written to
determine model-free scaling factors along the intensity and
time axes that optimally superimposed the curve in the
presence of the antibody against the curve in its absence
using least-squares criteria.
Molecular dynamics and modelling
Molecular dynamics simulations of the wild-type and
Trento AAT were performed with GROMACS 5.0.4 [49] based
on the wild-type AAT structure (PDB accession 1QLP);
hydrogens were added, the system solvated with TIP3P
water (≥ 10 A between protein and box boundaries), and
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neutralized with Na+/Cl at a concentration of 150 mM.
Simulations were conducted at 310 K using the amber99-sb
force field, the PME method for Coulomb interactions and
a Lennard-Jones potential (cut-off of 10 A) for short-range
interactions. After energy minimization, equilibration at
constant volume for 100 ps and constant pressure for
100 ps, the production run was performed in the NPT
ensemble (temperature control by velocity rescaling with a
characteristic time of 0.1 ps; pressure control using the Par-
rinello–Rahman method with a time constant of 1 ps and a
compressibility of 4.5∙105 bar1). Hydrogen bonds were
determined with a ≤ 3.5 A acceptor–donor distance and
≤ 30 ° hydrogen-donor-acceptor angle. For each acceptor–
donor pair, the number of hydrogen bonds was calculated
every 2 ps in 10 independent 10-ns simulations, and the
average of these values was taken.
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